Final IBRX Deadline Reminder: May 26, 2026 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP
PR Newswire
RADNOR, Pa., May 22, 2026
Did you buy IBRX securities between January 19, 2026, and March 24, 2026?Affected IBRX Investor SummaryWho: ImmunityBio, Inc. (NASDAQ: IBRX)What: Securities fraud class action lawsuit filedClass Period: January 19, 2026 through March 24, 2026Deadline to Seek Lead Plaintiff Status: May 26, 2026Key Lawsuit Allegations: Material misstatements and/or omissions concerning the company's lead biologic product, Anktiva.Investor Action: Contact Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) for recovery optionsRADNOR, Pa., May 22, 2026 /PRNewswire/ -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, informs investors that a securities fraud class action lawsuit has been filed against ImmunityBio, Inc. (ImmunityBio) (NASDAQ: IBRX) on behalf of those who purchased or acquired ImmunityBio securities between January 19, 2026, and March 24, 2026, inclusive. The lawsuit is filed in the United States District Court for the Central District of California and is captioned Douglas v. ImmunityBio, Inc., Case No. 2:26-cv-03261 (C.D. Cal.). Investors have until May 26, 2026, to file for lead plaintiff status.
